Navigation Links
Questcor Reports Record Second Quarter Financial Results
Date:7/24/2014

0; The significant increase in net sales was driven by increased prescribing of Acthar by physicians for patients suffering from rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, polymyositis, nephrotic syndrome, multiple sclerosis exacerbations, infantile spasms and symptomatic sarcoidosis – all FDA-approved indications for Acthar.  BioVectra, the Company's specialty manufacturing subsidiary, had net sales of $17.4 million in the second quarter of 2014, an increase of 131% from $7.5 million in the second quarter of 2013.  This increase was driven by increased demand for BioVectra's specialty pharmaceutical fermentation and synthetic manufacturing capabilities.  GAAP earnings for the second quarter of 2014 were $1.54 per diluted common share, up 37% from the year ago quarter.  Second quarter 2014 non-GAAP earnings per share were $1.85, an increase of 37% from the prior year period.

Net sales for the second quarter of 2013 included the effect of the Company's decision to accrue, based on information received in the quarter, an incremental Medicaid rebate liability of $11.5 million related to Questcor's 2001 entry into the Medicaid system subsequent to Questcor's acquisition of Acthar in 2001. 

Questcor shipped 8,850 vials of Acthar during the second quarter of 2014, which represents a new record for Acthar shipments in a quarter and an increase of 26% from the 7,050 vials shipped in the year ago quarter. Quarterly vial shipments are subject to significant variation due to several factors, including the size and timing of individual orders received from Questcor's distributor.  The timing of when these orders are received and filled can significantly affect net sales and net income in any particular quarter.  The Company believes that investors should consider the Company's results over several quarters when analyzing the Company's performance.

"Acthar prescription activity accelerated
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction
2. Questcor Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
3. Products Recall, Stock Price Updates, Technology Solution Deployment, Update on Extension Trial, and Donations - Research Report on Alexion Pharma, Questcor, BioMarin Pharma, Allscripts, and Prana
4. Questcor Provides Donation In Support Of Childrens Hospital & Research Center Oakland
5. Partnerships, Appointments, New Products, Public Offerings, and Agreements - Research Report on Questcor Pharmaceuticals, Hologic, IDEXX, Endologix, and Healthways
6. Questcor Announces Quarterly Cash Dividend and Provides Update on Share Repurchase Program
7. Questcor Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference
8. Biologics License Applications, Event Participations, and Stock Movements - Research Report on Baxter, WellPoint, Questcor Pharmaceuticals, CareFusion, and Hologic
9. Product Reviews, Recognitions, FDA Responses, and New Leadership Appointments - Research Report on Gilead, WellPoint, Questcor, Forest Laboratories, and Envision Healthcare
10. Questcor Honored as an "Everyday Hero" by NephCure Foundation
11. Questcor Adds G. Kelly Martin to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015   Leatt Corporation  (OTCQB: LEAT), a ... for all forms of sports, including extreme motor sports, ... announced today that the UISP Lega Motociclismo Lombardia, an ... riders to wear a neck brace during its racing ...
(Date:1/23/2015)... , Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE ... specializes in the development and sale of patented biopharmaceutical ... active pharmaceutical ingredients (API) today announced the business and ... operation. 1. Following the September 2014 JCM ...
(Date:1/22/2015)... - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a ... cardiovascular disease and overall health is pleased to provide you ... its outlook for 2015 from the CEO, Mr. Eugene ... would like to take this opportunity to share with you ...
Breaking Medicine Technology:Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... Nov. 10, 2010 NeoStem, Inc. (NYSE Amex: ... U.S. and China, announced today that Chief Executive Officer Robin ... developments at the Company at the LifeTech Capital Miami Medical ... Miami on November 12, 2010. In addition, Dr. Smith has ...
... Biotechnology Corporation ( www.generex.com ) (OTC Bulletin Board: ... subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ), has been ... the United States Internal Revenue Service (IRS) and the ... the Patient Protection and Affordable Care Act of ...
Cached Medicine Technology:NeoStem to Present at LifeTech Capital Miami Medical Investors Conference 2Generex Oncology Awarded Two IRS Therapeutic Discovery Project Grants 2Generex Oncology Awarded Two IRS Therapeutic Discovery Project Grants 3
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz Chiropractic ... treated just about every type of injury that can result from ... same twenty-plus years, the team at Doctors on Liens ... possible doctor. With the combined breadth of experience between ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... WASHINGTON, DC (PRWEB) January 22, 2015 ... conditions in vulnerable communities and cause financial distress to ... report by analysts at Howard University’s Center on Race ... of dollars in economic activity, payday loans at the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Compare-autoinsurance.org has released a ... insured by an auto insurance policy . , Some ... policy. Clients should check the newly released blog post to see ... cars and dangerously damaged vehicles are some of the cars that ...
(Date:12/26/2014)... 2014 The US represents the largest market ... 2013, GlobalData’s forecast estimates that sales of branded therapies were ... to the high incidence of the disease, high drug treatment ... and China. Increased sales of CRC therapies over the forecast ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... Christine Mummery, one of the worlds leading heart stem cell ... Dame Anne McLaren in the keynote lecture of the inaugural ... McLaren was an early pioneer of the study of embryonic ... of IVF treatments and stem cell techniques. , Prof Mummery ...
... natural fatty acids that is sometimes used as a weight-loss ... substances to prevent health problems that can follow rapid weight ... a compound naturally found in some meat and dairy products, ... a recent study in mice found that the hormone leptin ...
... to Complement Renowned Laboratory Information System, ... Inc. (OTC Bulletin Board: GLOB), an international,e-Health, ... its,Wyndgate Technologies(R) (Wyndgate) division has formed a ... CERN ), a,leading provider of healthcare ...
... MIAMI, April 9, 2008 Eurosport Active World, ... World, Corp. and,Eagle International Holdings Group, Inc. have ... Corp., whose common stock,trades on the "Pink Sheets" ... Inc. have merged. Subsequent to a 1000:1 reverse ...
... could be missed, harming long-term survival, study suggests , , ... analysis of breast cancer patient survival suggests it might ... node biopsies. , A team of New York City ... to be free of cancerous cells in their sentinel ...
... April 9, 2008 /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited ... marketer of medical devices in China with a ... Cheng, Mindray,s,executive vice president of strategic development and ... the JPMorgan 4th Annual China,Conference to be held ...
Cached Medicine News:Health News:Heart stem cell scientist to honor pioneering woman scientist in keynote speech 2Health News:Dietary oil may need help in avoiding any side effects of weight loss 2Health News:Dietary oil may need help in avoiding any side effects of weight loss 3Health News:Global Med Technologies(R), Inc. and Cerner Announce Strategic Alliance 2Health News:Global Med Technologies(R), Inc. and Cerner Announce Strategic Alliance 3Health News:Breast Cancer Lymph Node Biopsy May Need Closer Look 2Health News:Breast Cancer Lymph Node Biopsy May Need Closer Look 3Health News:Breast Cancer Lymph Node Biopsy May Need Closer Look 4Health News:Mindray to Attend the JPMorgan 4th Annual China Conference 2
... The Calypte AwareTM HIV-1/2 OMT test ... in vitro immunoassay for the,detection of antibodies ... and Type 2 (HIV-2) in human oral,mucosal ... as a point-of-care aid in the clinical ...
... the first HbA1c control available with intact ... HbA1c procedure including the lysing of the ... ready-to-use liquid control with an open-vial stability ... of six months when refrigerated. A1c-Cellular is ...
...
...
Medicine Products: